Alector/$ALEC
1D1W1MYTD1Y5YMAX
About Alector
Alector Inc is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative diseases. The company advances a pipeline of product candidates including Nivisnebart (AL101/GSK4527226) for Alzheimer's disease, AL137 for Alzheimer's disease, AL050 for Parkinson's disease and Lewy body dementia, and AL064, an siRNA program targeting tau for Alzheimer's disease and other tauopathies, supported by its proprietary Alector Brain Carrier (ABC) platform designed to improve delivery of therapeutics across the blood-brain barrier.
- Ticker
- $ALEC
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 103
- Headquarters
- South San Francisco, United States
- Website
- www.alector.com
Alector Metrics
BasicAdvanced
$252M
-
-$1.09
0.58
-
Price and volume
Market cap
$252M
Beta
0.58
52-week high
$3.40
52-week low
$1.09
Average daily volume
1.2M
Financial strength
Current ratio
5.26
Quick ratio
5.047
Long term debt to equity
-137.402
Total debt to equity
-328.566
Profitability
EBITDA (TTM)
-119.029
Gross margin (TTM)
-615.07%
Net profit margin (TTM)
-850.13%
Operating margin (TTM)
-891.32%
Effective tax rate (TTM)
-0.25%
Revenue per employee (TTM)
$130,000
Management effectiveness
Return on assets (TTM)
-27.62%
Return on equity (TTM)
-385.11%
Valuation
Price to revenue (TTM)
17.69
Price to book
-25.31
Price to tangible book (TTM)
-25.31
Price to free cash flow (TTM)
-1.548
Free cash flow yield (TTM)
-64.59%
Free cash flow per share (TTM)
-1.46
Growth
Revenue change (TTM)
-82.91%
Earnings per share change (TTM)
-6.82%
3-year revenue growth (CAGR)
-48.59%
3-year earnings per share growth (CAGR)
-14.29%
What the Analysts think about Alector
Analyst ratings (Buy, Hold, Sell) for Alector stock.
Alector Financial Performance
Revenues and expenses
Alector Earnings Performance
Company profitability
Alector News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.